Increased Tissue Factor Expression is an Independent Predictor of Mortality in Clear Cell Carcinoma of the Kidney

Abstract

ARTICLE INFO ______________________________________________________________ ______________________Purpose: Increased expression of tissue factor (TF), a primary initiator of the extrinsic coagulation pathway, has been associated with a worse prognosis in a variety of solid tumors. We report for the first time the correlation of the immunohistochemical expression of tissue factor with clinical and pathological outcomes in clear cell carcinomas of the kidney. Materials and Methods: immunohistochemical expression of tissue factor was evaluated in 58 paraffin-embedded samples of clear cell carcinomas of the kidney treated at the same university hospital, that was correlated with clinical and pathological variables and with overall survival. Results: high intensity tissue factor expression (TF area > 10µm 2 ) was observed in 22.4% of the tumors (13 patients), and was an important predictor of overall mortality, both in univariate and multivariate analysis (p < 0.05). Median overall survival for both groups was 66 months; 78.2 months for patients in the group of lower TF expression and 27.5 months for patients in the group of higher TF expression (log rank p < 0.001). The hazard ratio for mortality was 9.7 (CI 3.7-25.6) for tumors with increased TF expression. Conclusions: Increased immunohistochemical expression of TF was an important independent predictor of mortality in a contemporary cohort of patients with clear cell carcinoma of the kidney. Further studies are necessary to define the role of TF in clinical practice.

Serum tissue factor as a biomarker for renal clear cell carcinoma

“…In the samples of patients with Wilms tumors, an increased TF expression was an independent prognostic factor of overall survival (HR 5.6; p<0.01) ( 20 ). In samples of patients with clear cell RCC an increased expression of TF was also an independent predictor of overall survival (HR 4.03; p=0.03) ( 21 ). Förster et al have previously studied TF both in tissue and in serum of patients with RCC.…”

“…Serum TF levels were tested as possible tumor markers in ovarian and pancreatic cancers, with promising results ( 18 , 19 ). We have previously reported that an increased immunohistochemical expression of TF in Wilms tumors ( 20 ) and in clear cell RCC ( 21 ) was an adverse prognostic factor, correlated with decreased overall and cancer-specific survival. The present study aims to determine whether serum levels of TF are useful as biomarkers in clear cell RCC.…”

The role of tissue factor in metastasising, neoangiogenesis and hemostasis in cancer

“…При онкологических заболеваниях экспрессия TF изменяется по сравнению с его экспрессией в здоровом организме. Клетки множества типов злокачественных новообразований содержат значительное количество TF, что было показано с помощью иммуногистологического анализа образцов злокачественных тканей пациентов [2,12,[49][50][51][52], иммунохимического анализа клеточных культур [53] и анализа полимеразной цепной реакции (ПЦР) мРНК TF в опухолевых клетках различных типов [50,[52][53][54].…”

“…Опухоли мочеполовой системы светлоклеточный рак почки Экспрессия tf. Для светлоклеточного рака почки [2] высокая экспрессия TF характерна для III и IV стадий по TNM-классификации, низкая -для I и II стадий.…”

“…прогностическое значение экспрессии tf. При опухолях почек общая выживаемость пациентов выше при более низкой экспрессии TF опухолевыми клетками [1,2].…”